 |
Trials |
ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group; EORTC protocol 1410-BTG/AbbVie protocol M14-483Cancer type: Head and Neck cancer Phase: II Principal Investigator: Mäenpää Hanna Country: FI Keywords: Finland, Helsinki Status: Inclusion completed Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02343406?term=2014-004438-24&rank=1 |